HMG-CoA reductase inhibitors improve acute ischemic stroke outcome

Stroke. 2005 Jun;36(6):1298-300. doi: 10.1161/01.STR.0000165920.67784.58. Epub 2005 May 5.

Abstract

Background and purpose: Statins reduce the risk of stroke recurrence, but the benefits of statins in improving outcome of acute stroke patients have not been well explored.

Methods: We assessed potential effects of statins initiated before or within 4 weeks of stroke on 90-day outcome. Favorable outcomes were National Institutes of Health Stroke Scale (NIHSS) score < or =2 at 12 weeks and modified Rankin Scale (mRS) < or =2.

Results: Before stroke, 129 patients were receiving statins, 123 initiated statins within 4 weeks, and 600 patients were not on statins. Multivariate logistic regression analysis demonstrated that poststroke statins were associated with a significant probability of a favorable outcome at 12 weeks [NIHSS (P=0.002; OR, 1.92; CI, 1.27 to 2.91) and mRS (P=0.033; OR, 1.57; CI, 1.04 to 2.38)], whereas prestroke statins demonstrated a trend toward significance.

Conclusions: These preliminary results suggest that statin use may improve outcome of acute ischemic stroke.

MeSH terms

  • Aged
  • Brain Ischemia / drug therapy*
  • Cerebral Hemorrhage / drug therapy
  • Cerebrovascular Disorders / drug therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Odds Ratio
  • Recurrence
  • Regression Analysis
  • Risk
  • Severity of Illness Index
  • Stroke / drug therapy*
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors